Drug-Coated Balloons for In-Stent Restenosis

A paclitaxel-coated balloon reduced target-lesion failure better than an uncoated balloon.

In-stent restenosis occurs in up to 10% of patients undergoing percutaneous coronary intervention (PCI) with contemporary drug-eluting stents. In this multicenter, randomized trial, investigators assessed the efficacy and safety of a drug-coated balloon versus an uncoated balloon for treatment of in-stent restenosis.

Six hundred patients were randomized 2:1 to receive a paclitaxel-coated balloon or an uncoated balloon during PCI. Baseline characteristics were similar between groups; mean age was 68 years, 26% of participants were women, and 43% of patients had multiple-layer in-stent restenosis.

The incidence of the primary composite endpoint — ischemia-driven target-lesion revascularization, target-vessel myocardial infarction, or cardiac de…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)